Tumor <i>NLRP3</i> Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression
Bala Theivanthiran(University of North Carolina at Chapel Hill), Brent A. Hanks(University of North Carolina at Chapel Hill)
Cited by 0
Related Papers
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy
|Journal of Clinical Investigation|2020|248
Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
|Cancer Immunology Research|2015|178
Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti–PD-1 immunotherapy
|Science Translational Medicine|2022|53
Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling
|bioRxiv (Cold Spring Harbor Laboratory)|2024|1